Difference between revisions of "Part:BBa K5271005:Design"

(→‎References)
(→‎Source)
Line 12: Line 12:
 
===Source===
 
===Source===
  
−
Fc Fragment
+
Heave chain of human IgG
  
 
===References===
 
===References===

Revision as of 09:40, 2 October 2024


Fc fragment


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BamHI site found at 165
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 342
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Avoid fusing Fc fragment to nanobody when using a prokaryotic system. Insufficient secretion and formation Inclusion bodies were found when expressing the Fc-fused nanobody in E. Coli.

Source

Heave chain of human IgG

References

  • Kulemzin, S. V., Chikaev, N. A., Volkova, O. Y., Kuznetsova, V. V., Taranin, A. V., & Gorchakov, A. A. (2017). Modular lentiviral vectory system for optimization of chimeric antigen receptor design. Russ J Bioorganic Chem, 43, 1-9.
  • Jin, B. K., Odongo, S., Radwanska, M., & Magez, S. (2023). NANOBODIES®: A Review of Generation, Diagnostics and Therapeutics. International journal of molecular sciences, 24(6), 5994.
  • Bao, G., Tang, M., Zhao, J., & Zhu, X. (2021). Nanobody: a promising toolkit for molecular imaging and disease therapy. EJNMMI research, 11, 1-13.
  • Klint, J. K., Senff, S., Saez, N. J., Seshadri, R., Lau, H. Y., Bende, N. S., ... & King, G. F. (2013). Production of recombinant disulfide-rich venom peptides for structural and functional analysis via expression in the periplasm of E. coli. PloS one, 8(5), e63865.
  • De Marco, A. (2020). Recombinant expression of nanobodies and nanobody-derived immunoreagents. Protein expression and purification, 172, 105645.